AI-generated research brief — verify at source
Panax Ginseng Significantly Reduces Fatigue in GI Cancer Survivors Over Four Weeks
A randomized, double-blind, placebo-controlled trial found that four weeks of standardized Panax ginseng extract (250 mg/day) produced a clinically meaningful reduction in fatigue scores compared to placebo in gastrointestinal cancer survivors, with an adjusted mean difference of −1.38 points on the Brief Fatigue Inventory (95% CI: −1.90, −0.86; Cohen’s d = −1.26). The effect size is notably large, though the small single-center sample warrants caution in generalizing these results.
What Was Studied
This trial investigated whether standardized Panax ginseng extract could reduce cancer-related fatigue (CRF) in survivors of gastrointestinal malignancies who remained symptomatic at least four months after completing treatment. CRF is among the most persistent and functionally disabling sequelae of cancer treatment, and effective, well-tolerated interventions remain limited, making the evaluation of botanical supplements with mechanistic plausibility a meaningful research priority.
How It Was Studied
The researchers conducted a randomized, double-blind, placebo-controlled trial enrolling 65 GI cancer survivors who reported moderate-to-severe fatigue, defined as a Brief Fatigue Inventory (BFI) total score above 4. Participants were at least four months post-treatment and were randomly allocated to receive either 250 mg per day of standardized Panax ginseng extract or an identical-appearing placebo for four weeks. Fatigue severity was measured at baseline and at the end of the intervention period. The primary analysis used ANCOVA to compare post-intervention BFI scores while controlling for baseline values, and Cohen’s d was calculated to quantify effect size.
What Was Observed
- Fatigue severity dropped substantially in the ginseng group compared to the placebo group after four weeks. The intervention group’s mean BFI score fell from 5.36 to 3.99, while the placebo group’s score remained essentially unchanged at 5.37, yielding an adjusted between-group difference of −1.38 points — a reduction that was both statistically significant and associated with a large effect size (95% CI: −1.90, −0.86; Cohen’s d = −1.26, p < 0.001). A Cohen’s d of this magnitude (exceeding 1.0) is considered large by conventional benchmarks, suggesting the difference is not merely statistical noise.
- Beyond overall fatigue, the ginseng group showed significant improvements across multiple functional and quality-of-life dimensions assessed by BFI subscales, including general activity levels, ability to walk, mood, and enjoyment of life. These domain-specific gains suggest the intervention may support broader daily functioning rather than affecting fatigue perception alone.
- No treatment-related adverse events were recorded in either group throughout the four-week trial, indicating that the 250 mg/day dosing regimen was well tolerated in this population.
Why This Matters
Prior studies of Panax ginseng for cancer-related fatigue have produced inconsistent results, and evidence specific to gastrointestinal cancer survivors has been sparse. This trial adds a well-controlled data point to that literature, with baseline score matching between arms strengthening causal inference. The large observed effect size, if replicated in larger cohorts, would position standardized ginseng extract as a pharmacologically simple and tolerable addition to supportive care strategies for CRF, a condition with few robustly effective treatments.
How to Read This Result
The small sample of 65 participants from a single center, combined with a short four-week follow-up, limits the generalizability of these findings and makes replication in larger, multicenter trials essential before drawing firm conclusions about efficacy.
Limitations
The abstract does not explicitly report study limitations, though the authors themselves acknowledge the need for larger multicenter studies with extended follow-up periods to confirm these preliminary findings.